Side Effects during Treatment of Advanced Gastric Carcinoma by Chemotherapy Combined with CIK-cell Transfusion in Elderly People

References

1. ↵
   1. Gallo A and
   2. Cha C.

   Updates on esophageal and gastric cancers. World J Gastroenterol 2006; 12: 3237-3242.

   OpenUrlPubMedWeb of Science
2. ↵
   1. Chen FX,
   2. Liu JQ,
   3. Zhang NZ, et al.

   Clinical observation on adoptive immunotherapy with autologous cytokine-induced killer cells for advanced malignant tumor. Ai Zheng 2002; 21: 797-801 (Chinese).

   OpenUrlPubMed
3. ↵
   1. Chen L,
   2. Tian H,
   3. Chen J, et al.

   Surgical management of gastric stump cancer: a report of 37 cases. J Zhejiang Univ Sci B 2005; 6: 38-42.

   OpenUrlCrossRefPubMed
4. ↵
   1. Abe M,
   2. Nishimura Y,
   3. Shibamoto Y.

   Intraoperative radiation therapy for gastric cancer. World J Surg 1995; 19: 544-547.

   OpenUrlPubMed
5. ↵
   1. Bresciani C,
   2. Gama-Rodrigues J,
   3. Strassmann V, et al.

   Long term (five-year) survival following radical surgical treatment plus adjuvant chemotherapy (FAM) in advanced gastric cancer: a controlled study. Rev Hosp Clin Fac Med Sao Paulo 2000; 55: 129-136.

   OpenUrlPubMed
6. ↵
   1. Jiang J,
   2. Xu N,
   3. Wu C, et al.

   Treatment of advanced gastric cancer by chemotherapy combined with au-tologous cytokine-induced killer cells. Anticancer Res 2006; 26: 2237-2242.

   OpenUrlAbstract/FREE Full Text
7. ↵
   1. Jiang J,
   2. Wu C,
   3. Chen X, et al.

   Analysis of the therapeutic effect of tumour infiltrating lymphocytes on malignant pleural effusion in aged. Chin J Geriatrics. 1999; 18: 35-37 (Chinese).

   OpenUrl
8. ↵
   1. Schmidt-Wolf GD,
   2. Negrin RS,
   3. Schmidt-Wolf IG.

   Activated T cells and cytokine-induced CD3⁺CD56⁺ killer cells. Ann Hematol 1997; 74: 51-56.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Kollmannsberger C,
   2. Budach W,
   3. Stahl M, et al.

   Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO. Ann Oncol 2005; 16:1326-1333.

   OpenUrlCrossRefPubMedWeb of Science
10. ↵
    1. Lin WL,
    2. Li DG,
    3. Chen Q, et al.

    Clinical and experimental study of oxaliplatin in treating human gastric carcinoma. World J Gastroenterol 2004; 10: 2911-2915.

    OpenUrlPubMed
11. ↵
    1. Klautke G,
    2. Foitzik T,
    3. Ludwig K, et al.

    Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma. Strahlenther Onkol 2004;180: 695-700.

    OpenUrlPubMed
12. ↵
    1. Zuo Y,
    2. Xu M,
    3. Shen D, et al.

    Postoperative intraperitioneal hyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. Chin J Oncol 2004; 26: 247-249 (Chinese).

    OpenUrl
13. ↵
    1. Bozzetti F,
    2. Vaglini M,
    3. Deraco M.

    Intraperitoneal hyperthermic chemotherapy in gastric cancer: rationale for a new approach. Tumori 1998; 84: 483-488.

    OpenUrlPubMed
14. ↵
    1. Yu QS,
    2. Zhang FZ,
    3. Tang XR.

    Clinical study on early use of Chinese medicinal herbs and chemotherapy after operation of gastric cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi 1995; 15: 459-461 (Chinese).

    OpenUrlPubMed
15. ↵
    1. Wang GT.

    Treatment of operated late gastric carcinoma with prescription of strengthening the patient’s resistance and dispelling the invading evil in combination with chemotherapy: follow-up study of 158 patients and experimental study in animals. Zhong Xi Yi Jie He Za Zhi 1990; 10: 712-716, 707 (Chinese).

    OpenUrlPubMed
16. ↵
    1. Catalano V,
    2. Labianca R,
    3. Beretta GD, et al.

    Gastric cancer. Crit Rev Oncol Hematol 2005; 54: 209-241.
17. ↵
    1. Herberman RB.

    Cancer therapy by biological response modifiers. Clin Physiol Biochem 1987; 5: 238-248.

    OpenUrlPubMedWeb of Science
18. ↵
    1. Margolin KA,
    2. Negrin RS,
    3. Wong KK, et al.

    Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 1997; 157: 231-240.

    OpenUrlCrossRefPubMed